Delivery Order HHSN272201600001I-HHSN27200001

This definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to The Johns Hopkins University to operate a facility for testing malaria vaccines in adult human subjects. The $14,621,520.76 contract, which does not have a set-aside designation, commenced on September 30, 2004 and is scheduled for completion on December 2, 2014. The Johns Hopkins University, a private non-profit research university, has a long history of supporting federal...

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $40,505 firm-fixed-price purchase order to Charles River Laboratories, Inc. to perform characterization testing of Pichia master and working cell banks. This work supports ongoing research at the Laboratory of Malaria Immunology and Vaccinology to develop a malaria transmission-blocking vaccine candidate. The testing will demonstrate the identity, purity,...

This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Kaiser Foundation Health Plan of Washington as the prime contractor. The $2,436,780.34 contract is for services related to the Vaccine Treatment and Evaluation Units (VTEU) program, a major NIH initiative focused on vaccine research and development. The contract supports a clinical trial evaluating the safety and efficacy of the GAP3KO...

This is a $3,397,349.60 fixed-price level of effort contract awarded by the U.S. Department of the Navy's Bureau of Medicine and Surgery to Sanaria Inc., a veteran-owned biotechnology company, for a Phase III clinical trial of an investigational malaria vaccine. The contract is for the production and delivery of Plasmodium falciparum sporozoites, the parasite that causes malaria, to support the clinical trial. Sanaria Inc. has previously provided services to the National Institutes of Health and...

This federal contract award is for Protocol Development (base) and Protocol Implementation (options 1-6) services related to a Phase II clinical trial (Protocol 14-0112) to evaluate the safety, reactogenicity, and immunogenicity of the M-001 influenza A/H7N9 vaccine in healthy volunteers. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, under the Vaccine and Treatment Evaluation Units...

This contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS - NIH - NIAID) is for a COVID-19 related seroprevalence study to be conducted in Mali by The Mitchell Group, Inc. from June 16, 2022 to November 30, 2022. The scope of work involves assessing the spread of SARS-CoV-2, the virus that causes COVID-19, by testing for antibodies in human blood samples to determine what percentage of the...

The University of Massachusetts Medical School was awarded a $7.45 million cost-no-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and manufacture a GMP-grade Neisseria gonorrhoeae multi-peptide vaccine candidate known as TMCP2 and advance it through a Phase I clinical trial. Three subcontracts were issued in support of this effort, including to Advanced Bioscience Laboratories to perform immunogenicity testing,...

This is a $417,953.02 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Icon Government and Public Health Solutions, Inc. to execute a clinical trial protocol (NCT02210325). The contract has no set-aside designation. Icon Government and Public Health Solutions, Inc., a global contract research organization, is the prime contractor. It has subcontracted portions of...

This is a federal contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit organization that manufactures goods. The contract is a delivery order under the Simian Vaccine Evaluation Units 2013-2020 master indefinite-delivery/indefinite-quantity (IDIQ) contract, with a potential value of $846,362.98. The purpose is to...

Bioreliance Corporation, a foreign-owned for-profit organization, was awarded a $34,978 firm-fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) to provide endotoxin, sterility, and general safety testing services in support of investigational new drug (IND) applications for NIAID's Pfs230D1-CRM197 and Pfs230D1-EPA malaria vaccine products. The contract, which does not have a set-aside designation, runs through August 31, 2024. Bioreliance has...